Nanoparticle-Based Drug Delivery

This paper develops a library of PEG-lipids to enhance paclitaxel solubility and cytotoxicity in fluid micellar nanoparticles, finding that double-PEG-lipid 2k2 significantly improves solubility and efficacy.

This study compares nanoparticle uptake by HepaRG cells and macrophages, showing PMLABe-based NPs are efficiently internalized while PEGylated variants show reduced uptake, and GBVA10-9 peptide does not significantly affect uptake.

This paper develops a 3-in-1 nanotherapeutic approach combining cisplatin, olaparib, and metformin for ovarian cancer, showing stability and enhanced therapeutic effects in vitro.

This paper demonstrates that bottlebrush PEG nanocarriers can translocate across human airway epithelium via enhanced endocytosis due to their unique molecular architecture.

This study investigates the limits of EPR-driven tumor accumulation using non-opsonizing nanomaterials and finds that maximum tumor accumulation is around 60% ID/g with limited selectivity and variability across tumors.

This paper develops pH-sensitive nanodroplets for controlled berberine chloride delivery, showing high encapsulation efficiency and ultrasound-enhanced release.

This paper develops a real-time FRET-based system to monitor nanocarrier behavior and drug release at post-stroke microthrombi in vivo.

This study demonstrates that targeted NAD+ delivery via nanocarriers reduces intimal hyperplasia and promotes endothelial regeneration in a rat model of restenosis.

This paper designs and evaluates nanomaterials that disassemble in response to HDAC enzymes, revealing a mechanism based on deacetylation-induced amphiphilicity reduction.

This paper describes a method to coat living cell membranes onto nanoparticles, demonstrating improved biocompatibility and reduced phagocytosis.

This study evaluates a nanoparticle-formulated ACAT1 inhibitor in mice, showing brain delivery and reduced AD pathology without toxicity.

This study demonstrates that SSHELs, synthetic bacterial spore-like particles, can deliver chemotherapy to HER2-positive cancer cells with reduced toxicity and effectiveness in tumor models.

The paper identifies molecular markers associated with nanomedicine distribution in tumor tissue using spatial transcriptomics and fluorescence imaging.

The paper presents a spatio-temporal PKPD model for nanoparticle-based drugs, showing improved fidelity over existing models in mouse experiments with 13 NPs.

This study introduces a graph-based PKPD model for nanoparticles to predict treatment outcomes, achieving high fitting accuracy in in vivo experiments.

This paper develops multifunctional phosphate-based nanoparticles for imaging and targeted doxorubicin delivery to breast cancer cells, showing reduced cytotoxicity and effective drug delivery.

The paper demonstrates that dye-functionalized lipid nanocarriers can deliver a PI3Kγ inhibitor to hepatocytes, restoring liver function in sepsis without affecting immune responses.

This study evaluates hybrid nanoparticles for delivering cholesterol to the brain in Huntington disease, showing improved targeting, controlled release, and therapeutic benefits without inflammation.

This paper develops a nanoparticle formulation of vismodegib that improves its efficacy for medulloblastoma treatment by enhancing CNS pharmacokinetics and reducing systemic toxicity.

This study evaluates the neurotoxic effects of chitosan-dextran sulfate nanocomplexes on neural cells in vitro and finds reduced viability and neurite length.